Duet BioTherapeutics is a clinical stage immuno-oncology company pioneering the development of bifunctional oligonucleotides to address “undruggable” targets such as STAT3. The company’s mission is to discover and develop therapeutic solutions that empower the human immune system to restore health, even when faced with seemingly intractable, treatment-resistant cancer. Duet integrates the management and clinical development of the immunotherapy assets of Scopus BioPharma and Olimmune, a company acquired by Scopus in June 2021, and founded by Marcin Kortylewski, Ph.D. and John Rossi, Ph.D.